HORIZON 2020 PROJECT | Tumor-LN-oC FOLLOW-UP MEETING

The meeting, which was attended by all 11 partners with representatives from microfluidics, cell biology, cancer biology, physics, computer programming and regulatory affairs fields, was the first presential meeting of the Tumor-LN-oC consortium, allowing the participants to meet in person after six months of working together.

The meeting, which was attended by all 11 partners with representatives from microfluidics, cell biology, cancer biology, physics, computer programming and regulatory affairs fields, was the first presential meeting of the Tumor-LN-oC consortium, allowing the participants to meet in person after six months of working together.
November 22, 2021

Asphalion experts Marta Morales and Mariana Gómez participated in the 6-month follow-up meeting of Horizon 2020 project Tumor-LN-oC that took place in Athens last week. The meeting, which was attended by all 11 partners with representatives from microfluidics, cell biology, cancer biology, physics, computer programming and regulatory affairs fields, was the first presential meeting of the Tumor-LN-oC consortium, allowing the participants to meet in person after six months of working together.

The EU-funded Tumor-LN-oC project proposes the development and validation of a TRL 5 tumor-lymph node-on-chip (Tumor-LN-oC) platform composed of 3D tissue models and microfluidic chips which will connect surgically removed human primary tumors and LN tissue from the same lung cancer patient. This will serve as a “biological twin” of the patient and will allow to study the interaction of primary tumors with LNs for individual patients.

For a complete overview about the project, we invite you to have a look at the press release: https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC-press-release.pdf

For further information you can contact us at: info@asphalion.com

 

Search News & Events

  • Filter by category

Share

Related news and events

ETERNAL PROJECT | 6-month meeting

Collaborative project to boost reduction of the environmental impact of pharmaceutical products through their entire life cycle

EChiLiBRiST | 1st Consortium General Assembly

The project is funded by The European Union under the Horizon Europe Programme and counts with the participation of 12 institutions from Europe, the United Kingdom, Africa and Canada and will be implemented on a duration of 5 years.

The METHYLOMIC project has been kicked off!

The efficiency and cost-effectiveness will also be assessed in great detail, and experts will guide regulatory approval to ensure delivery of the first epigenetic kit personalised treatment of CD.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting